Abstract
ABSTRACTBuruli ulcer disease is a neglected necrotizing and disabling cutaneous tropical illness caused by Mycobacterium ulcerans (Mul). Fluoroquinolone (FQ), used in the treatment of this disease, has been known to act by inhibiting the enzymatic activities of DNA gyrase; however, the detailed molecular basis of these characteristics and the FQ resistance mechanisms in Mul remains unknown. This study investigated the detailed molecular mechanism of Mul DNA gyrase and the contribution of FQ resistance in vitro using recombinant proteins from the Mul subsp. shinshuense and Agy99 strains with reduced sensitivity to FQs. The IC50 of FQs against Ala91Vla and Asp95Gly mutants of Mul shinshuense and Agy99 GyrA subunits were 3.7- to 42.0-fold higher than those against wild-type enzyme. Similarly, the CC25 was 10- to 210-fold higher than those for the WT enzyme. Furthermore, the interaction between the amino acid residues of WT/mutant Mul DNA gyrase and FQ side chains was assessed via molecular docking studies. This is the first detailed study showing the contribution of Mul DNA GyrA subunit mutations to reduce the susceptibility against FQs.
Publisher
Cold Spring Harbor Laboratory
Reference40 articles.
1. WHO. 2000. Buruli Ulcer; Mycobacterium ulcerans infection. World Health Organization WHO/CDS/CPE/GBU/2000.1.
2. Buruli Ulcer (M. ulcerans Infection): New Insights, New Hope for Disease Control
3. Former Buruli Ulcer Patients’ Experiences and Wishes May Serve as a Guide to Further Improve Buruli Ulcer Management
4. WHO. 2013. Sustaining the drive to overcome the global impact of neglected tropical diseases. World Health Organization ISBN 978 92 4 156454 0.
5. Revisiting Buruli ulcer